At present, clinical validity for PCR-based ctDNA testing has been recognized by the FDA (Food and Drug Administration) in the United States and by the EMA (European Medicines Agency) in Europe, and has been approved for EGFR mutation detection in patients with advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.